Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Agile Therapeutics Inc. (AGRX) is an innovative women's healthcare company focused on developing non-daily contraceptive solutions through its proprietary transdermal technology. This page serves as the definitive source for verified news and official announcements related to product developments, regulatory milestones, and corporate updates.
Investors and healthcare professionals will find comprehensive coverage of Twirla® contraceptive patch updates, financial performance reports, and strategic partnership announcements. Our curated collection ensures timely access to earnings releases, clinical trial progress, and manufacturing updates while maintaining strict adherence to factual reporting standards.
Key information categories include FDA regulatory communications, research advancements in transdermal drug delivery, and market expansion initiatives. All content is rigorously verified to provide reliable insights into the company's position within the women's health sector.
For those monitoring AGRX's progress in contraceptive innovation, we recommend bookmarking this page and checking regularly for essential updates. Our commitment to neutral, accurate reporting makes this your trusted resource for understanding Agile Therapeutics' role in advancing patient-centric healthcare solutions.
Agile Therapeutics (Nasdaq: AGRX) has launched Twirla, the first and only once-weekly contraceptive patch in the U.S. It delivers a low-dose combination of levonorgestrel and ethinyl estradiol, targeting women with a BMI less than 30 kg/m². Twirla is designed for convenience and less frequent administration compared to daily pills, with a commitment to accessibility and affordability for users. Safety warnings include reduced effectiveness in women with higher BMI, cardiovascular risks for smokers, and other contraindications. The patch is supported by resources like "The Loop" for user education.
Agile Therapeutics (Nasdaq: AGRX) announced the publication of primary results from the Phase 3 SECURE study of Twirla®, a transdermal contraceptive system, in the journal Contraception. The study, which included 2,032 women, evaluated Twirla's efficacy, safety, and tolerability. It was approved by the FDA on February 14, 2020, for women with a BMI < 30 kg/m². The publication is expected to provide healthcare providers with vital information to enhance shared decision-making regarding contraceptive options.
Agile Therapeutics (Nasdaq: AGRX) announced that CEO Al Altomari will participate in a virtual fireside chat at the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The pre-recorded chat is available on the company's website from 10:00am ET on November 23 through December 3. Agile is a women's healthcare company focusing on fulfilling unmet health needs, particularly in contraceptive options, with its product Twirla®, a non-daily prescription contraceptive.
Agile Therapeutics (AGRX) announced its financial results for Q3 2020, reporting $71.9 million in cash and equivalents as of September 30. The company is on track for the commercial launch of Twirla, expected by year-end 2020, with all three validation batches ready for release. The net loss for the quarter increased to $15.5 million, or $0.18 per share, compared to $4.4 million the previous year. Operating expenses narrowed to $52-$54 million for 2020, with significant investments in sales and marketing.
Agile Therapeutics (Nasdaq: AGRX) announces it will release its third quarter 2020 financial results on November 12, 2020, after market close. A live conference call and webcast will follow at 4:30 p.m. ET for discussing the results and providing a business update. Investors can join the conference call by calling (877) 407-2991 for U.S. callers or (201) 389-0925 internationally. The company focuses on women's healthcare, particularly offering contraceptive options through its product Twirla®, utilizing its Skinfusion® transdermal technology.
Agile Therapeutics, a women's healthcare company traded under the symbol AGRX, will have Chairman and CEO Al Altomari present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020, at 3:20 PM EDT. The presentation will be available via a live webcast, and an archived version will be accessible on the company’s website for 30 days.
Agile focuses on developing contraceptive options, including its product Twirla®, a non-daily prescription contraceptive using proprietary Skinfusion® technology.
Agile Therapeutics, a women’s healthcare firm, announced that CEO Al Altomari will engage in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference. This event is scheduled for September 16, 2020, at 11:30 a.m. EDT. A live webcast will be accessible on the company’s Investor Relations page, with an archived version available for 30 days post-event. Agile is dedicated to addressing women’s healthcare needs and offers innovative contraceptive solutions via its product, Twirla®, a transdermal contraceptive system.
Agile Therapeutics (Nasdaq: AGRX) announced a virtual Investor/Analyst Day on September 21, 2020, from 11:00 AM to 1:00 PM EDT. Key executives will discuss the Twirla commercial program, including launch activities and marketing strategies. Presenters include CEO Al Altomari, CFO Dennis Reilly, and notable speakers from the OB/GYN field. A live audio webcast will be available, and an archived version can be accessed for 30 days post-event. Twirla is a non-daily contraceptive patch designed to meet women's health needs.
Agile Therapeutics (Nasdaq: AGRX) has launched the I'm So Done campaign, aimed at empowering women to actively participate in their contraceptive choices. This initiative focuses on educating women about different birth control options and encourages dialogue with healthcare providers. The campaign emphasizes the importance of informed decision-making in contraceptive care. According to the Guttmacher Institute, women seeking two children will use contraception for about three decades, highlighting the need for diverse choices throughout their lives.
Agile Therapeutics, a women's healthcare company, announced that its CEO, Al Altomari, will participate in a panel at Maxim Group’s M-Vest Virtual Conference on August 13, 2020, at 10:00 a.m. Eastern Time. This event will be moderated by Jason McCarthy, a biotechnology analyst at Maxim Group. Agile Therapeutics focuses on providing innovative contraceptive options, including its non-daily prescription system, Twirla. For registration details, visit here.
